HomeProductsBioactive CompoundsDNA Damage & RepairTopoisomeraseRubitecan
Chemical structure of CAS 91421-42-0

Rubitecan

In Stock•Starting at $139 for 50 mg•Purity ≥ 98%
CAS No.91421-42-0
MDL No.MFCD06656294
MFC20H15N3O6
MW393.30
InChI KeyVHXNKPBCCMUMSW-FQEVSTJZSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg98%$139In Stock
100 mg98%$165In Stock
250 mg98%$410In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Rubitecan is a pyranoindolizinoquinoline derivative of camptothecin, with a nitro group replacing the hydrogen at position 9. It functions as a prodrug for 9-aminocamptothecin. It acts as an antineoplastic agent, an EC 5.99.1.2 DNA topoisomerase inhibitor, and is classified as a C-nitro compound, a semisynthetic derivative, a tertiary alcohol, and a delta-lactone.

CAS No.91421-42-0
Product NameRubitecan

Biological Targets

TOP1

Associated Conditions

urinary bladder cancer·endometrial cancer·urethra cancer·cutaneous melanoma·colorectal cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).

International journal of oncology • Vol. 20, Issue 1 • 2002
PMID: 11743646

Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • Vol. 62, Issue 1 • 2002
PMID: 11830313DOI: 10.1016/s0167-8140(01)00465-0

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 8, Issue 3 • 2002
PMID: 11895891

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.

Anti-cancer drugs • Vol. 13, Issue 2 • 2002
PMID: 11901310DOI: 10.1097/00001813-200202000-00009

Documentation

Similar Products